Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Matteo Dell'Olio"'
Autor:
Anna Lucania, Antonio La Sala, Giovanni D'Arena, Francesco Saverio Mantuano, Lucia Mastrullo, Eustachio Miraglia, Cascavilla Nicola, Matteo Dell’Olio, Scalzulli Rp, Michele Nobile, Grazia Sanpaolo
Publikováno v:
Leukemia & Lymphoma. 52:1222-1229
The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean ag
Autor:
Nicola Cascavilla, Saverio Mantuano, Lucia Mastrullo, Giovanni D'Arena, Antonio Abbadessa, Maria Rosaria Villa, Matteo Dell’Olio, Antonio La Sala, Maria Luigia Vigliotti, Potito Rosario Scalzulli
Publikováno v:
European Journal of Haematology. 82:235-239
We report four patients (mean age 65 yr; range 40-77 yr) affected by acquired pure red cell aplasia (PRCA) complicating chronic lymphoid disorders and treated with anti-CD20 monoclonal antibody rituximab. Three out of four patients were given packed
Publikováno v:
Leukemia & Lymphoma. 46:1321-1327
Primary breast lymphomas (PBL) are uncommon neoplasms. Seven PBL were diagnosed between March 1993 and October 2002. A lumpectomy (n = 4) or radical mastectomy (n = 3) was performed; 5 patients were in clinical stage (CS)II and 2 in CS IV; 6 patients
Autor:
Carla Cavalli, Caterina Stelitano, Chiara Broglia, Edoardo Ascari, Laura Dezza, Paolo G. Gobbi, Dimitri Luisi, Emilio Iannitto, Matteo Dell’Olio, Stefano Molica, Massimo Federico, Francesco Merli, Raffaella Bertè
Publikováno v:
Cancer. 98:2393-2401
BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS. One hundred forty-three patients w
Autor:
Nicola Cascavilla, Carlo Bodenizza, Antonietta Falcone, Matteo Dell’Olio, Pellegrino Musto, Saverio Mantuano, Michele Nobile, Lorella Melillo, Angelo Michele Carella, Grazia Sanpaolo, Potito Rosario Scalzulli, Antonio La Sala
Publikováno v:
Leukemia & Lymphoma. 44:1545-1548
Ninety patients with untreated, stage I-II A myeloma, were randomised to receive or not monthly infusions of pamidronate (PMD) for 1 year, without additional therapies. Follow-up ranged from 36 to 72 months (median 51 months). Three years after the s
Autor:
Francesco Di Raimondo, Francesco Angrilli, Alessandro Pulsoni, Alessandra Tucci, Stefano Sacchi, Francesco Merli, Matteo Dell’Olio, Massimo Federico, Angelo Michele Carella, Luca Arcaini, Alessandra Dondi, Sara Galimberti, Gianluca Gaidano, Luigi Marcheselli, Umberto Vitolo, Maura Brugiatelli, Caterina Stelitano, Vito Franco, Stefano Luminari, Luigi Rigacci
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(12)
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter
Autor:
Giampiero Romano, Giuseppe Mele, Nicola Di Renzo, Angelo Michele Carella, Clelia Musto, Antonio La Sala, Maria Luigia Vigliotti, Matteo Dell’Olio, Alfredo Tartarone
Publikováno v:
The Hematology Journal. 5:453-455
Autor:
Giovanni Rossi, Matteo Dell’Olio, Nicola Cascavilla, Daniela Valente, Giovanni D'Arena, Maria Marta Minervini, Potito Rosario Scalzulli, Lorella Melillo, Michele Nobile, Grazia Sanpaolo, A. Falcone
Publikováno v:
International journal of immunopathology and pharmacology. 24(3)
The incidence of acute myeloid leukemia (AML) increases with age, but results of intensive chemotherapy in elderly patients are disappointing. Non-pegylated liposomal formulations of doxorubicin (Myocet™) have been developed with the aim of reducin
Autor:
Stefano Luminari, Francesco Merli, Paolo G. Gobbi, Massimo Federico, Caterina Stelitano, Donato Mannina, Matteo Dell’Olio, Maura Brugiatelli, Elisa Barbolini, Gianfranco Giglio, Giuseppe Polimeno, Luca Baldini, Alessandra Dondi
We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988 to 2004 with PROMECE-CYTABOM (P-C) plus involved-field radiation therapy (IF-RT). At th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a7ceb7f90e56ff5e753a782edd5657
https://hdl.handle.net/11380/644692
https://hdl.handle.net/11380/644692
Publikováno v:
British journal of haematology. 143(2)